Loading…
Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis
HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treat...
Saved in:
Published in: | BMC health services research 2016-10, Vol.16 (1), p.573-573, Article 573 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13 |
---|---|
cites | cdi_FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13 |
container_end_page | 573 |
container_issue | 1 |
container_start_page | 573 |
container_title | BMC health services research |
container_volume | 16 |
creator | Vanclooster, Annick Wollersheim, Hub Vanhaecht, Kris Swinkels, Dorine Aertgeerts, Bert Cassiman, David |
description | HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treated or monitored optimally. The purpose of this study was to develop key-interventions (KI's) to measure and improve the quality of care delivered to patients diagnosed with HH.
A RAND-Modified Delphi method was used to develop KI's. In the first round of a scoring form to prioritize the recommendations extracted from evidence-based guidelines was circulated between experts. The results of this survey were discussed in a consensus meeting, followed by a final appraisal of the selected recommendations. This resulted in a list of measurable KI's.
Initially, 41 key recommendations on screening, diagnosis and treatment/management were extracted from three existing guidelines on HH (European Association for the Study of the Liver, American Association for the Study of Liver Diseases and Dutch guideline on HH). Finally, a core set of 24 recommendations resulted in 15 KI's.
This manuscript presents the results of the process to develop KI's to measure and improve the quality of care for patients with HH. |
doi_str_mv | 10.1186/s12913-016-1835-2 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5062877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A466442270</galeid><sourcerecordid>A466442270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13</originalsourceid><addsrcrecordid>eNptUstu1DAUtRCIloEPYIMssWHj4tc4yQapqlqKqMQG1pbj3ExcJfZgJ1N1yZ9zp1NKi5AXftxzju_jEPJW8BMhavOxCNkIxbgwTNRqzeQzcix0JZlpjHr-6HxEXpVyzbmoalm9JEeyqpQS6_qY_PoKtyzEGfIO4hxSLLSDHHbQ0T6nic5DBqCwCx1ED7R1BSObBa9jiFBonzKdXHQbmJBPXUReGsd0w5YtTT3dujlgoNCbMA_08uKcDg6m5AcUd3MqobwmL3o3Fnhzv6_Ij4vz72eX7Orb5y9np1fM60bPDIwE0xrldWuaVtaqAfCd9s5zhyU2jWtxYT-8cr6Vhtd102kB0gG0GoRakU8H3e3STtB5zCq70W5zmFy-tckF-zQSw2A3aWfX3MgaG7YiH-4Fcvq5QJntFIqHcXQR0lLsfgSaN1Lsoe__gV6nJUcs7w7FlcRZ_EVt3Ag2xD7hv34vak-1MVpLWXFEnfwHhauDKfgUoQ_4_oQgDgSfUykZ-ocaBbd739iDbyz65i4dK5Hz7nFzHhh_jKJ-A4t4wHI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835032001</pqid></control><display><type>article</type><title>Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>ABI/INFORM Global</source><creator>Vanclooster, Annick ; Wollersheim, Hub ; Vanhaecht, Kris ; Swinkels, Dorine ; Aertgeerts, Bert ; Cassiman, David</creator><creatorcontrib>Vanclooster, Annick ; Wollersheim, Hub ; Vanhaecht, Kris ; Swinkels, Dorine ; Aertgeerts, Bert ; Cassiman, David ; Haemochromatosis working group ; on behalf of the Haemochromatosis working group</creatorcontrib><description>HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treated or monitored optimally. The purpose of this study was to develop key-interventions (KI's) to measure and improve the quality of care delivered to patients diagnosed with HH.
A RAND-Modified Delphi method was used to develop KI's. In the first round of a scoring form to prioritize the recommendations extracted from evidence-based guidelines was circulated between experts. The results of this survey were discussed in a consensus meeting, followed by a final appraisal of the selected recommendations. This resulted in a list of measurable KI's.
Initially, 41 key recommendations on screening, diagnosis and treatment/management were extracted from three existing guidelines on HH (European Association for the Study of the Liver, American Association for the Study of Liver Diseases and Dutch guideline on HH). Finally, a core set of 24 recommendations resulted in 15 KI's.
This manuscript presents the results of the process to develop KI's to measure and improve the quality of care for patients with HH.</description><identifier>ISSN: 1472-6963</identifier><identifier>EISSN: 1472-6963</identifier><identifier>DOI: 10.1186/s12913-016-1835-2</identifier><identifier>PMID: 27733158</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Care and treatment ; Chronic obstructive pulmonary disease ; Clinical trials ; Consensus ; Continuity of Patient Care ; Delphi method ; Delphi Technique ; Diabetes ; Disease ; Evidence-Based Practice ; Gastroenterology ; Genetic Diseases, Inborn ; Guidelines as Topic ; Hemochromatosis ; Humans ; Liver cancer ; Liver cirrhosis ; Liver Diseases ; Male ; Medical care ; Osteoporosis ; Patient care planning ; Practice guidelines (Medicine) ; Primary care ; Quality Improvement ; Quality management ; Quality of Health Care ; Risk factors</subject><ispartof>BMC health services research, 2016-10, Vol.16 (1), p.573-573, Article 573</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>The Author(s). 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13</citedby><cites>FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062877/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1835032001?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11688,25753,27924,27925,36060,36061,37012,37013,44363,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27733158$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vanclooster, Annick</creatorcontrib><creatorcontrib>Wollersheim, Hub</creatorcontrib><creatorcontrib>Vanhaecht, Kris</creatorcontrib><creatorcontrib>Swinkels, Dorine</creatorcontrib><creatorcontrib>Aertgeerts, Bert</creatorcontrib><creatorcontrib>Cassiman, David</creatorcontrib><creatorcontrib>Haemochromatosis working group</creatorcontrib><creatorcontrib>on behalf of the Haemochromatosis working group</creatorcontrib><title>Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis</title><title>BMC health services research</title><addtitle>BMC Health Serv Res</addtitle><description>HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treated or monitored optimally. The purpose of this study was to develop key-interventions (KI's) to measure and improve the quality of care delivered to patients diagnosed with HH.
A RAND-Modified Delphi method was used to develop KI's. In the first round of a scoring form to prioritize the recommendations extracted from evidence-based guidelines was circulated between experts. The results of this survey were discussed in a consensus meeting, followed by a final appraisal of the selected recommendations. This resulted in a list of measurable KI's.
Initially, 41 key recommendations on screening, diagnosis and treatment/management were extracted from three existing guidelines on HH (European Association for the Study of the Liver, American Association for the Study of Liver Diseases and Dutch guideline on HH). Finally, a core set of 24 recommendations resulted in 15 KI's.
This manuscript presents the results of the process to develop KI's to measure and improve the quality of care for patients with HH.</description><subject>Analysis</subject><subject>Care and treatment</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Clinical trials</subject><subject>Consensus</subject><subject>Continuity of Patient Care</subject><subject>Delphi method</subject><subject>Delphi Technique</subject><subject>Diabetes</subject><subject>Disease</subject><subject>Evidence-Based Practice</subject><subject>Gastroenterology</subject><subject>Genetic Diseases, Inborn</subject><subject>Guidelines as Topic</subject><subject>Hemochromatosis</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Diseases</subject><subject>Male</subject><subject>Medical care</subject><subject>Osteoporosis</subject><subject>Patient care planning</subject><subject>Practice guidelines (Medicine)</subject><subject>Primary care</subject><subject>Quality Improvement</subject><subject>Quality management</subject><subject>Quality of Health Care</subject><subject>Risk factors</subject><issn>1472-6963</issn><issn>1472-6963</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>M0C</sourceid><sourceid>PIMPY</sourceid><recordid>eNptUstu1DAUtRCIloEPYIMssWHj4tc4yQapqlqKqMQG1pbj3ExcJfZgJ1N1yZ9zp1NKi5AXftxzju_jEPJW8BMhavOxCNkIxbgwTNRqzeQzcix0JZlpjHr-6HxEXpVyzbmoalm9JEeyqpQS6_qY_PoKtyzEGfIO4hxSLLSDHHbQ0T6nic5DBqCwCx1ED7R1BSObBa9jiFBonzKdXHQbmJBPXUReGsd0w5YtTT3dujlgoNCbMA_08uKcDg6m5AcUd3MqobwmL3o3Fnhzv6_Ij4vz72eX7Orb5y9np1fM60bPDIwE0xrldWuaVtaqAfCd9s5zhyU2jWtxYT-8cr6Vhtd102kB0gG0GoRakU8H3e3STtB5zCq70W5zmFy-tckF-zQSw2A3aWfX3MgaG7YiH-4Fcvq5QJntFIqHcXQR0lLsfgSaN1Lsoe__gV6nJUcs7w7FlcRZ_EVt3Ag2xD7hv34vak-1MVpLWXFEnfwHhauDKfgUoQ_4_oQgDgSfUykZ-ocaBbd739iDbyz65i4dK5Hz7nFzHhh_jKJ-A4t4wHI</recordid><startdate>20161013</startdate><enddate>20161013</enddate><creator>Vanclooster, Annick</creator><creator>Wollersheim, Hub</creator><creator>Vanhaecht, Kris</creator><creator>Swinkels, Dorine</creator><creator>Aertgeerts, Bert</creator><creator>Cassiman, David</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161013</creationdate><title>Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis</title><author>Vanclooster, Annick ; Wollersheim, Hub ; Vanhaecht, Kris ; Swinkels, Dorine ; Aertgeerts, Bert ; Cassiman, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis</topic><topic>Care and treatment</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Clinical trials</topic><topic>Consensus</topic><topic>Continuity of Patient Care</topic><topic>Delphi method</topic><topic>Delphi Technique</topic><topic>Diabetes</topic><topic>Disease</topic><topic>Evidence-Based Practice</topic><topic>Gastroenterology</topic><topic>Genetic Diseases, Inborn</topic><topic>Guidelines as Topic</topic><topic>Hemochromatosis</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Diseases</topic><topic>Male</topic><topic>Medical care</topic><topic>Osteoporosis</topic><topic>Patient care planning</topic><topic>Practice guidelines (Medicine)</topic><topic>Primary care</topic><topic>Quality Improvement</topic><topic>Quality management</topic><topic>Quality of Health Care</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vanclooster, Annick</creatorcontrib><creatorcontrib>Wollersheim, Hub</creatorcontrib><creatorcontrib>Vanhaecht, Kris</creatorcontrib><creatorcontrib>Swinkels, Dorine</creatorcontrib><creatorcontrib>Aertgeerts, Bert</creatorcontrib><creatorcontrib>Cassiman, David</creatorcontrib><creatorcontrib>Haemochromatosis working group</creatorcontrib><creatorcontrib>on behalf of the Haemochromatosis working group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC health services research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vanclooster, Annick</au><au>Wollersheim, Hub</au><au>Vanhaecht, Kris</au><au>Swinkels, Dorine</au><au>Aertgeerts, Bert</au><au>Cassiman, David</au><aucorp>Haemochromatosis working group</aucorp><aucorp>on behalf of the Haemochromatosis working group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis</atitle><jtitle>BMC health services research</jtitle><addtitle>BMC Health Serv Res</addtitle><date>2016-10-13</date><risdate>2016</risdate><volume>16</volume><issue>1</issue><spage>573</spage><epage>573</epage><pages>573-573</pages><artnum>573</artnum><issn>1472-6963</issn><eissn>1472-6963</eissn><abstract>HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treated or monitored optimally. The purpose of this study was to develop key-interventions (KI's) to measure and improve the quality of care delivered to patients diagnosed with HH.
A RAND-Modified Delphi method was used to develop KI's. In the first round of a scoring form to prioritize the recommendations extracted from evidence-based guidelines was circulated between experts. The results of this survey were discussed in a consensus meeting, followed by a final appraisal of the selected recommendations. This resulted in a list of measurable KI's.
Initially, 41 key recommendations on screening, diagnosis and treatment/management were extracted from three existing guidelines on HH (European Association for the Study of the Liver, American Association for the Study of Liver Diseases and Dutch guideline on HH). Finally, a core set of 24 recommendations resulted in 15 KI's.
This manuscript presents the results of the process to develop KI's to measure and improve the quality of care for patients with HH.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27733158</pmid><doi>10.1186/s12913-016-1835-2</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1472-6963 |
ispartof | BMC health services research, 2016-10, Vol.16 (1), p.573-573, Article 573 |
issn | 1472-6963 1472-6963 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5062877 |
source | Open Access: PubMed Central; Publicly Available Content Database; ABI/INFORM Global |
subjects | Analysis Care and treatment Chronic obstructive pulmonary disease Clinical trials Consensus Continuity of Patient Care Delphi method Delphi Technique Diabetes Disease Evidence-Based Practice Gastroenterology Genetic Diseases, Inborn Guidelines as Topic Hemochromatosis Humans Liver cancer Liver cirrhosis Liver Diseases Male Medical care Osteoporosis Patient care planning Practice guidelines (Medicine) Primary care Quality Improvement Quality management Quality of Health Care Risk factors |
title | Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A45%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Key-interventions%20derived%20from%20three%20evidence%20based%20guidelines%20for%20management%20and%20follow-up%20of%20patients%20with%20HFE%20haemochromatosis&rft.jtitle=BMC%20health%20services%20research&rft.au=Vanclooster,%20Annick&rft.aucorp=Haemochromatosis%20working%20group&rft.date=2016-10-13&rft.volume=16&rft.issue=1&rft.spage=573&rft.epage=573&rft.pages=573-573&rft.artnum=573&rft.issn=1472-6963&rft.eissn=1472-6963&rft_id=info:doi/10.1186/s12913-016-1835-2&rft_dat=%3Cgale_pubme%3EA466442270%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1835032001&rft_id=info:pmid/27733158&rft_galeid=A466442270&rfr_iscdi=true |